Valuation: Simulations Plus, Inc.

Market Cap 371M 325M 300M 280M 528M 35.11B 540M 3.61B 1.39B 17.32B 1.39B 1.36B 60.14B P/E 2026 *
44x
P/E 2027 * 40.6x
Enterprise Value 371M 325M 300M 280M 528M 35.11B 540M 3.61B 1.39B 17.32B 1.39B 1.36B 60.14B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 4.31x
Free-Float
82.79%
Yield 2026 *
-
Yield 2027 * -
1 day+0.99%
1 week+1.55%
Current month+7.42%
1 month+7.42%
3 months+60.95%
6 months+0.60%
Current year+0.82%
1 week 18.14
Extreme 18.14
18.4
1 month 15.29
Extreme 15.2901
18.56
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.42
Extreme 7.4201
90.92
Manager TitleAgeSince
Chief Executive Officer 67 2018-06-25
Director of Finance/CFO 63 2020-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 1996-07-16
Chairman 76 2024-12-16
Director/Board Member 58 2014-12-02
Date Insider Type Main position Quantity % Market Cap.
Jun. 15Fiscal year

Executive/Senior Manager

22,050 0.1094%
Jun. 14Fiscal year

Executive/Senior Manager

3,150 0.0156%
Jun. 02Sell

Executive/Senior Manager

-1,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+0.99%+1.55%+9.02%-57.00% 371M
+2.84%+15.06%-37.82%-9.70% 28.63B
+3.03%+17.64%-28.64%+209.92% 14.19B
+0.44%-2.92%-22.09%+50.91% 5.4B
-2.24%+2.98% - - 3.01B
+2.67%+6.42% - - 2.17B
+1.97%+5.79%+39.28%-43.95% 1.86B
+0.95%+4.66%-18.37% - 1.3B
+0.14%+4.44%-35.40%+241.86% 758M
+2.23%-6.69%-43.59%-61.37% 731M
Average +1.34%+4.09%-17.20%+47.24% 5.84B
Weighted average by Cap. +2.28%+11.07%-30.33%+58.00%

Financials

2026 *2027 *
Net sales 81.71M 71.54M 66.04M 61.67M 116M 7.72B 119M 795M 307M 3.81B 307M 300M 13.23B 86.2M 75.47M 69.68M 65.06M 122M 8.15B 125M 838M 324M 4.02B 324M 317M 13.96B
Net income 9.02M 7.9M 7.29M 6.81M 12.82M 853M 13.11M 87.76M 33.88M 421M 33.88M 33.14M 1.46B 9.71M 8.5M 7.85M 7.33M 13.8M 918M 14.11M 94.44M 36.46M 453M 36.46M 35.66M 1.57B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
26-06-29 $18.38 +0.99% 660,870
26-06-26 $18.20 +0.33% 1,162,293
26-06-25 $18.14 -0.17% 689,848
26-06-24 $18.17 +0.11% 507,402
26-06-23 $18.15 +0.28% 632,660
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.38USD
Average target price
17.25USD
Spread / Average Target
-6.15%

Quarterly revenue - Rate of surprise